About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Chapters
Books
News
Editorials
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Scientometrics
Impact Factor
Discipline Ranks
H-Index
G-Index
Articles
Citations
Article Citations
Citation Distribution
Search This Journal
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
exaly
›
Journals
›
Clinical Therapeutics
›
Top Articles
Clinical Therapeutics
Pharmacology
3.4
(top 4%)
Impact Factor
3.8
(top 4%)
extended IF
136
(top 2%)
H-Index
2.1K
authors
7.8K
papers
152.3K
citations
8.7K
citing journals
72.6K
citing authors
Most Cited Articles of Clinical Therapeutics
Title
Year
Citations
A systematic review of the associations between dose regimens and medication compliance
2001
1.7K
Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice
1999
605
Recognition and treatment of hyponatremia in acutely ill hospitalized patients
2007
551
Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity
2000
487
Capecitabine: a review
2005
451
Immunogenicity of therapeutic proteins: clinical implications and future prospects
2002
433
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
2006
431
Evaluating quality-of-life and health status instruments: development of scientific review criteria
1996
431
The cost of treating community-acquired pneumonia
1998
420
Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies
2006
388
Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir
2001
356
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
2015
353
Childhood obesity: a review of increased risk for physical and psychological comorbidities
2013
348
Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer
1999
341
Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials
2003
332
Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study
2007
326
Gut-Microbiota-Brain Axis and Its Effect on Neuropsychiatric Disorders With Suspected Immune Dysregulation
2015
314
Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group
2000
314
A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids
2001
301
Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study
2008
294
Current Challenges in Cancer Treatment
2016
293
Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability
2004
282
A review of diabetes treatment adherence and the association with clinical and economic outcomes
2011
277
Predictors of medication adherence in the elderly
1998
276
Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases
2008
270
How are inpact factors calculated?
The impact factor (IF) is calculated by counting citations from peer-reviewed journals only.
extended IF
also counts citations from books and conference papers. However, no patent, abstract, working papers, online documents, etc., are covered.
site/software ©
exaly
; All materials licenced under
CC by-SA
.